Carcinoma of the Adrenal Cortex

Carcinoma of the adrenal cortex—often shortened to adrenocortical carcinoma (ACC)—is a rare, aggressive cancer that starts in the outer layer (cortex) of the adrenal gland. Each person has two adrenal glands, one sitting on top of each kidney. The adrenal cortex makes steroid hormones such as cortisol, aldosterone, and androgens/estrogens. In ACC, cells in this layer grow out of control. The tumor may make extra hormones and cause strong body changes (for example Cushing syndrome, high blood pressure, or signs of too much male or female hormone). The tumor can grow into nearby tissues or spread (metastasize) to organs like the liver, lungs, or bones. ACC can occur at any age but is most common in early childhood and in adults in their 40s to 50s. It needs careful testing, a skilled team, and fast, structured treatment.

Carcinoma of the adrenal cortex—often called adrenocortical carcinoma (ACC)—is a rare, aggressive cancer that starts in the outer layer (cortex) of an adrenal gland. The adrenal glands sit on top of the kidneys and make key hormones such as cortisol, aldosterone, and androgens/estrogens. ACC can be functional (it makes excess hormones causing symptoms like high blood pressure, weight gain, or menstrual/sexual changes) or non-functional (it does not make hormones, so symptoms come from the growing mass). ACC is staged using systems such as ENSAT (European Network for the Study of Adrenal Tumors). Surgery with complete removal is the main chance of cure when the tumor is operable. If the cancer is advanced or returns, care usually combines drugs like mitotane (adrenal-targeting medicine), chemotherapy (such as EDP: etoposide, doxorubicin, cisplatin), and supportive treatments to control hormone excess. Because ACC is uncommon and complex, treatment at experienced centers is strongly recommended. PubMedESMO+1

Other names

Adrenocortical carcinoma; carcinoma of the adrenal cortex; adrenal cortex cancer; ACC; cortical adrenal carcinoma; primary adrenal cortical carcinoma; malignant adrenal cortical tumor; functional adrenocortical carcinoma (when it makes hormones); non-functional adrenocortical carcinoma (when it does not make hormones). In older texts you may see “malignant adrenal cortical neoplasm.” All mean the same basic disease: a cancer that begins in the hormone-making outer layer of the adrenal gland.

---

How the adrenal cortex normally works

The adrenal cortex has three zones. The outer zona glomerulosa makes aldosterone, which balances salt and water and helps control blood pressure. The middle zona fasciculata makes cortisol, which affects stress response, blood sugar, and immune function. The inner zona reticularis makes androgens (sex-related hormones). In ACC, cells from any of these zones can become cancerous. Many tumors still make some of these hormones, often in excess, which is why symptoms can be dramatic and helpful for diagnosis.

---

Types

1. Functional ACC
   The tumor makes extra hormones. People often have obvious symptoms such as Cushing features (from cortisol), signs of too much male hormone (acne, hair growth, deep voice), or signs of too much estrogen (breast enlargement in men or vaginal bleeding in post-menopausal women). Functional tumors are common in children and many adults with ACC.

2. Non-functional ACC
   The tumor does not make hormones in excess. Symptoms come from the mass itself—abdominal fullness, pain, or pressure—or from spread to other organs.

3. Localized vs. advanced ACC

   • Localized means the tumor is limited to the adrenal gland or nearby tissues and is potentially removable by surgery.

   • Advanced means it has spread to lymph nodes or distant organs (liver, lungs, bones, or elsewhere).

4. By stage (ENSAT system)
   Doctors stage ACC from I to IV based on size and spread. Lower stages are confined and higher stages indicate lymph node or distant spread.

5. By microscopic pattern (histologic variants)

   • Conventional ACC (most common).

   • Oncocytic ACC (cells look packed with mitochondria; sometimes behaves a bit differently).

   • Myxoid ACC (with a gelatinous stroma).
     These labels help pathologists describe the tumor but do not change the idea that this is a malignant adrenal cortical cancer.

6. Pediatric vs. adult ACC
   ACC can appear in children, often with signs of early puberty or virilization, and in adults, where Cushing features or a large abdominal mass are common. Some genetic causes are more frequent in children.

---

Causes and risk factors

Most ACC cases are sporadic, meaning we do not find a single clear cause. Still, several genetic syndromes and risk patterns increase risk. Think of these as risk factors or associations rather than guarantees.

1. Li-Fraumeni syndrome (TP53 mutation)
   A strong inherited cancer syndrome. A specific TP53 change (R337H) is common in parts of Brazil. It raises the chance of ACC, especially in children.

2. Beckwith-Wiedemann spectrum / 11p15 imprinting defects
   An overgrowth syndrome involving genes that regulate growth, including IGF2. Children with this syndrome have higher ACC risk.

3. Multiple Endocrine Neoplasia type 1 (MEN1)
   A genetic syndrome that mainly affects parathyroid, pituitary, and pancreas. Rarely, adrenal cortical tumors (including ACC) occur.

4. Lynch syndrome (hereditary non-polyposis colorectal cancer)
   A DNA repair defect syndrome. ACC is uncommon but reported.

5. Family history of ACC
   Having close relatives with ACC or related endocrine tumors can signal inherited risk.

6. Congenital adrenal hyperplasia (CAH)
   Long-term high ACTH drive and adrenal hyperplasia may be linked to adrenal tumors; malignant transformation is rare but reported.

7. TP53 founder mutation in Southern Brazil (R337H)
   A regional genetic risk that markedly increases pediatric ACC incidence.

8. Overexpression of IGF-2 pathway
   A common molecular feature in ACC. It is more a tumor “driver” than a lifestyle cause.

9. Wnt/β-catenin pathway changes (CTNNB1 mutations)
   Frequently found in ACC tissue and thought to promote tumor growth.

10. SF-1 (NR5A1) pathway dysregulation
    SF-1 is a key adrenal development factor. Overactivity can support tumor cell survival.

11. Female sex
    Adult ACC has a slight female predominance. This is an observation, not a “cause.”

12. Age extremes
    Highest risk in very young children and in adults in midlife. This bimodal pattern is typical.

13. Prior abdominal radiation (rare association)
    As with many cancers, high-dose prior radiation may increase risk, but this is uncommon.

14. Possible exposure to endocrine-disrupting chemicals
    Studies suggest possible links (e.g., certain pesticides), but evidence is limited and not definitive.

15. Long-standing adrenal adenoma that enlarges and changes
    Most adenomas stay benign. Rapid growth or new hormone excess raises concern for malignancy.

16. Chronic smoking (weak association)
    Clear proof is lacking, but smoking is a general cancer risk. It is sensible to avoid.

17. Obesity and metabolic stress (uncertain)
    Not proven causes, but obesity complicates blood pressure and glucose control and can mask symptoms.

18. Immune dysfunction (uncertain)
    No firm causal link, but severe immune problems can affect cancer surveillance.

19. Other overgrowth syndromes or hemihyperplasia
    Rare conditions with increased cell growth can be associated with adrenal tumors.

20. Truly unknown causes
    In most people with ACC, no specific trigger is found. Biology inside the tumor—mutations and pathway changes—drives its growth.

---

Symptoms and signs

Symptoms depend on which hormones are overproduced and on tumor size or spread.

1. Features of Cushing syndrome (too much cortisol)
   Weight gain in the face and trunk, round “moon” face, purple stretch marks, easy bruising, weak muscles, thin skin, mood changes, and high blood sugar.

2. High blood pressure
   Can occur from excess cortisol or aldosterone or simply from stress and pain. Often resistant to routine drugs.

3. Low potassium (from aldosterone excess)
   Causes muscle weakness, cramps, palpitations, and sometimes dangerous heart rhythm changes.

4. Virilization in females
   Acne, oily skin, extra facial/body hair (hirsutism), deepened voice, clitoral enlargement, and menstrual irregularity from excess androgens.

5. Feminization in males
   Breast enlargement (gynecomastia), decreased libido, erectile dysfunction, infertility from excess estrogens.

6. Early puberty in children
   Rapid growth, pubic hair, body odor, acne, genital changes before the normal age.

7. Abdominal pain or fullness
   A growing mass can stretch the capsule or press on nearby organs.

8. Unintended weight loss and fatigue
   Common with advanced cancer and with high cortisol.

9. Easy bruising and poor wound healing
   From excess cortisol and skin thinning.

10. Mood and sleep problems
    Anxiety, depression, irritability, and insomnia are common with cortisol excess.

11. Diabetes or worsening blood sugar control
    Cortisol raises glucose, so new diabetes can appear or control can worsen.

12. Bone loss and fractures
    Cortisol weakens bones, causing back pain or height loss.

13. Nausea or loss of appetite
    From tumor pressure or systemic illness.

14. New stretch marks and thin skin
    Classic in Cushing syndrome: purple, wide striae on abdomen, thighs, or arms.

15. Symptoms from spread
    Cough or shortness of breath (lung), jaundice or pain (liver), or bone pain (bones).

---

Diagnostic approach

Doctors first ask about symptoms and examine the body. Because many ACCs make hormones, the next step is hormone testing. Imaging then looks at the adrenal gland and the rest of the body to define tumor size and spread. If the tumor is likely removable, doctors usually avoid needle biopsy before surgery because of a small risk of spreading tumor cells. After surgery, pathology confirms the diagnosis and grades its aggressiveness. For non-removable disease, biopsy may be used to guide treatment. Below are key tests, grouped by the categories you requested.

A) Physical Examination

1. Focused blood pressure and vital signs check
   Purpose: find hypertension, fever, or rapid heart rate.
   What it shows: high readings suggest cortisol or aldosterone excess or stress from a large tumor.

2. Cushingoid feature assessment
   Purpose: look for moon face, fat pad on the back of the neck, purple stretch marks, easy bruising, thin skin.
   What it shows: supports cortisol excess from a functional tumor.

3. Sex-hormone effect exam
   Purpose: check for hirsutism, acne, voice changes in females; gynecomastia or testicular changes in males.
   What it shows: suggests excess androgens or estrogens.

4. Abdominal and flank palpation
   Purpose: feel for a mass, tenderness, or organ enlargement.
   What it shows: large adrenal tumors can sometimes be felt, though many are deep and not palpable.

5. Growth and general nutrition review
   Purpose: in children, plot height/weight on growth charts; in adults, note rapid changes.
   What it shows: early puberty or rapid growth suggests hormone-producing ACC.

B) Manual / Bedside Tests

6. Orthostatic (postural) blood pressure measurement
   Purpose: measure BP lying down and standing.
   What it shows: large drops suggest volume issues; persistent hypertension supports hormone excess.

7. Manual proximal muscle strength testing
   Purpose: check thigh and shoulder strength.
   What it shows: proximal weakness is common in Cushing syndrome.

8. Waist circumference and skin inspection
   Purpose: simple measurements and careful skin look.
   What it shows: central obesity, striae, and bruising support cortisol excess.

C) Laboratory and Pathological Tests

9. Serum electrolytes (especially potassium and sodium)
   Purpose: screen for low potassium (hypokalemia) and high sodium.
   What it shows: points toward aldosterone excess; also helps assess severity.

10. Overnight 1-mg dexamethasone suppression test (DST)
    Purpose: you take a small steroid pill at night; cortisol is measured the next morning.
    What it shows: if cortisol does not suppress, it suggests cortisol excess.

11. 24-hour urinary free cortisol (UFC)
    Purpose: collect urine for 24 hours to quantify cortisol production.
    What it shows: elevated UFC supports Cushing syndrome from a functional ACC.

12. Androgen panel (DHEA-S, testosterone, androstenedione)
    Purpose: measure adrenal and gonadal androgens.
    What it shows: high DHEA-S is common in adrenal origin; elevation supports a hormone-secreting tumor.

13. Aldosterone-to-renin ratio (ARR)
    Purpose: screen for primary aldosteronism.
    What it shows: high aldosterone with low renin suggests aldosterone-producing tumor.

14. Plasma free metanephrines
    Purpose: rule out pheochromocytoma (a different adrenal tumor) before any surgery or biopsy.
    What it shows: normal values make dangerous catecholamine spikes during surgery less likely.

15. Surgical pathology with Weiss score and Ki-67 index
    Purpose: after tumor removal, a pathologist confirms ACC and estimates aggressiveness.
    What it shows: a high Ki-67 (rapid cell division) and certain microscopic features indicate higher risk.

D) Electrodiagnostic Tests

16. Electrocardiogram (ECG)
    Purpose: quick heart rhythm test.
    What it shows: low potassium can cause specific ECG changes; hypertension also strains the heart.

17. Electromyography (EMG) in severe weakness
    Purpose: if muscle weakness is significant, EMG can assess muscle involvement.
    What it shows: may support steroid-related myopathy; not routine but helpful in select cases.

E) Imaging Tests

18. Adrenal protocol CT scan (with contrast and washout)
    Purpose: high-resolution images to see adrenal size, shape, and density.
    What it shows: features like size >4–6 cm, irregular borders, necrosis, and low contrast washout suggest malignancy; also checks local invasion and lymph nodes.

19. MRI of the adrenals (chemical-shift and contrast sequences)
    Purpose: detailed soft-tissue imaging to complement or replace CT when needed.
    What it shows: helps differentiate lipid-rich adenomas from ACC and assesses invasion into vessels like the inferior vena cava.

20. FDG PET-CT (for staging and treatment planning)
    Purpose: detect metabolically active cancer sites throughout the body.
    What it shows: identifies spread to lungs, liver, bones, or nodes; helps guide surgery, radiation, or systemic therapy plans.

Notes on biopsy: Needle biopsy of a suspected resectable ACC is often avoided before surgery due to a small risk of tumor seeding and because it rarely changes the plan when imaging and hormones strongly suggest ACC. Biopsy may be used when disease is unresectable or when the diagnosis is unclear and will change treatment.

Non-pharmacological treatments

Physiotherapy & physical rehabilitation 

1. Cancer-specific exercise program: gentle aerobic + resistance training to reduce fatigue, preserve muscle, and improve mood; started after surgical clearance, adapted around chemo cycles. Purpose: stamina and function. Mechanism: counters deconditioning and inflammation. Benefits: better energy, sleep, and daily activity.

2. Breathing training & inspiratory muscle work: useful after upper-abdominal surgery and for anxiety. Purpose: expand lungs, ease dyspnea. Mechanism: strengthens respiratory muscles. Benefits: fewer post-op chest issues.

3. Core and posture therapy: protects the back/abdomen after adrenalectomy. Purpose: safe movement. Mechanism: strengthens stabilizers. Benefits: less pain, faster recovery.

4. Balance and gait training: if weak or dizzy (steroids, low potassium). Purpose: fall prevention. Mechanism: proprioception/strength. Benefits: safety at home.

5. Flexibility and range-of-motion work: gentle stretching to limit stiffness from inactivity or steroids. Purpose: preserve mobility. Benefits: better comfort and reach.

6. Pelvic/trunk scar care and desensitization: post-surgery soft-tissue therapy (when healed). Purpose: reduce scar tightness. Benefits: easier bending/twisting.

7. Lymphedema-aware limb care education: if nodes removed; therapist teaches risk reduction. Purpose: prevent swelling. Benefits: comfort, infection reduction.

8. Fatigue management pacing (“energy budgeting”): plan/alternate activity and rest. Mechanism: matches limited energy to tasks. Benefits: less crash fatigue.

9. Safe strength building with bands/weights: low load/high rep under supervision. Benefits: maintains muscle against steroid catabolism.

10. Return-to-work/role training: graded exposure and ergonomics planning. Benefits: smoother reintegration.

11. Heat/cold modalities for pain (as appropriate): short, safe sessions guided by therapist. Benefits: symptom relief without extra drugs.

12. Pelvic floor support (when relevant): core synergy with breathing for abdominal support.

13. Post-operative walking plan: early mobilization reduces clots and speeds bowel recovery.

14. Falls-proofing the home: PT/OT recommendations; remove trip hazards, add rails.

15. Tele-rehab check-ins: maintain adherence between visits.

Mind-body & psychological care 

16. Psycho-oncology counseling/CBT: structured support for fear, mood, and coping; improves treatment adherence.

17. Mindfulness/relaxation training: breath, body scan, and guided imagery to reduce stress, pain, and insomnia.

18. Peer support groups (in-person/online): share experience, practical tips, reduce isolation.

19. Sleep hygiene coaching: regular schedule, light control, caffeine timing; protects mood and immunity.

20. Distress screening with fast referral: early identification of anxiety/depression.

21. Spiritual care (if desired): meaning-centered coping.

Education & safety coaching

22. “Steroid-sick-day” education (essential if on mitotane or steroid replacement): carry an emergency steroid card/bracelet; know stress-dose rules and when to seek urgent care.

23. Blood pressure, glucose, and weight self-monitoring (if hormone-secreting tumor or on steroids).

24. Medication-interaction and contraceptive counseling: mitotane lowers many drug levels and reduces efficacy of oral contraceptives; reliable contraception is required during and for months after therapy.

25. Vaccination review & infection-prevention basics: hand hygiene, food safety, and up-to-date vaccines per oncology team.

(Non-drug supportive care is emphasized in guidelines; it complements—not replaces—surgery/medical therapy.) PubMed

---

Drug treatments

Important safety note: dosing is individualized. The ranges below are typical examples used in practice; your oncology/endocrine team will adjust for you. Many of these medicines require treatment at expert centers and frequent monitoring.

1. Mitotane (adrenolytic; only drug specifically approved for ACC). Typical dosing: titrated to achieve therapeutic blood level (often 14–20 mg/L), starting low and increasing; can reach several grams/day in divided doses. Purpose: targets adrenal cortical cells and helps control hormone excess. Mechanism: destroys adrenal cortex cells and alters steroid metabolism. Key side effects: fatigue, GI upset, neurologic effects, high lipid levels; it induces liver enzymes and reduces other drug levels; often causes adrenal insufficiency requiring hydrocortisone replacement. EndokrinologiePubMed

2. EDP chemotherapy: Etoposide + Doxorubicin + Cisplatin (often combined with mitotane). Dosing/time: cyclical IV regimens every 3–4 weeks; exact doses per protocol. Purpose: first-line for advanced/metastatic ACC. Evidence: FIRM-ACT trial showed higher response and longer progression-free survival vs streptozocin+mitotane. Side effects: low blood counts, nausea, hair loss, neuropathy, kidney/cardiac risks; needs monitoring. PubMedNew England Journal of Medicine

3. Streptozocin (alkylating; alternative with mitotane when EDP not suitable). Purpose: palliative control. Side effects: nausea, kidney toxicity, marrow suppression. PubMed

4. Temozolomide (alkylating, off-label in ACC). Purpose: salvage therapy in some patients after standard regimens. Side effects: fatigue, low counts. (Evidence is limited; used case-by-case in centers.) PubMed

5. Pembrolizumab (PD-1 inhibitor, immunotherapy). Purpose: may help a subset with refractory ACC, especially if MSI-high/TMB-high. Mechanism: unleashes immune attack on cancer. Side effects: immune-related inflammation (thyroid, colon, liver, lungs). PubMed

6. Nivolumab ± Ipilimumab (PD-1 ± CTLA-4). Purpose: option in selected refractory cases within trials or specialized centers. Side effects: similar immune-related risks. PubMed

7. Cabozantinib / Lenvatinib / other TKIs (targeted anti-angiogenic agents). Purpose: off-label in selected patients when standard options fail; evidence is emerging and mixed. Side effects: hypertension, fatigue, thyroid changes, hand-foot syndrome. PubMed

8. Ketoconazole (steroidogenesis blocker). Purpose: quickly reduces cortisol when the tumor overproduces it (Cushing’s) while cancer therapy begins. Side effects: liver toxicity, drug interactions. PubMed

9. Metyrapone (steroid blocker). Purpose: rapid cortisol control. Side effects: hypertension, low potassium, hirsutism. Often combined with ketoconazole for strong control. PubMed

10. Osilodrostat (11β-hydroxylase inhibitor). Purpose: another option for cortisol excess control; specialist use. Side effects: adrenal insufficiency risk, low potassium, hypertension. PubMed

11. Mifepristone (glucocorticoid receptor blocker). Purpose: controls high blood sugar and symptoms from cortisol excess when enzyme blockers are not tolerated. Side effects: low potassium, endometrial thickening, drug interactions. PubMed

12. Spironolactone / Eplerenone (mineralocorticoid antagonists). Purpose: treat aldosterone-driven high blood pressure/low potassium until tumor control. Side effects: high potassium, gynecomastia (less with eplerenone). PubMed

13. Hydrocortisone (steroid replacement)—often required during mitotane therapy or after adrenalectomy because cortisol production drops. Purpose: prevent adrenal crisis; stress-dose during illness/surgery. Side effects: weight gain, glucose changes if overdosed. (Replacement guided by Endocrine/oncology team.) Endocrine SocietyPubMed

14. Fludrocortisone (mineralocorticoid replacement) when needed after bilateral adrenal damage or in adrenal insufficiency. Purpose: maintain salt/water balance. Side effects: high blood pressure, swelling, low potassium. Endocrine Society

15. Supportive medicines (anti-nausea, growth factor for low blood counts, bone protection if long-term steroids, PPI for GI protection). Purpose: keep you safe and on treatment. (Choice individualized per guideline.) PubMed

---

Dietary “molecular” supplements

There is no supplement proven to treat ACC. Nutrition aids symptom control, strength, and recovery. Always clear supplements with your oncology team to avoid drug interactions—especially because mitotane changes how the body handles many medicines. Endokrinologie

1. High-protein oral nutrition supplements (whey/casein/soy blends): support muscle during stress and steroid use; typical goal 1.2–1.5 g protein/kg/day from food + drinks.

2. Omega-3 (EPA/DHA) formulas for cancer-related weight loss (cachexia) support; common studied range 1–2 g/day EPA+DHA; watch bleeding risk.

3. Vitamin D3 (if low): supports bone while on steroids; dose per blood level (e.g., 800–2000 IU/day or repletion course).

4. Calcium (if dietary intake is low), especially with vitamin D when on steroids; dosing per clinician.

5. Magnesium (if low) to help with cisplatin-related losses and muscle cramps; guided by labs.

6. Potassium-rich foods/supplements (only if potassium is low and clinician approves), especially with aldosterone excess or after starting certain blockers.

7. Soluble fiber (oats/psyllium) to help steroid-related glucose swings and GI regularity; start low to avoid bloating.

8. Probiotics (select strains) for antibiotic-associated diarrhea prevention—discuss safety if neutropenic.

9. B-complex (food-first, supplement if deficient) to support energy pathways during chemo; avoid megadoses.

10. Multinutrient shakes tailored by oncology dietitian to meet calorie/protein goals on poor-appetite days.

(Because robust ACC-specific supplement trials are lacking, choices are individualized and aimed at nutrition gaps and treatment side-effect support.)

---

Immunity booster / regenerative / stem cell” drugs

There are no approved “stem cell drugs” or regenerative medicines for ACC. Using such products outside clinical trials can be unsafe. What does help immunity and recovery are evidence-based steps:

1. Seasonal and indicated vaccines (inactivated vaccines as advised during treatment schedules).

2. Growth-factor injections (e.g., G-CSF) during certain chemotherapy to prevent severe neutropenia—this is standard supportive oncology care, not a “booster.”

3. Antimicrobial prophylaxis if you become severely neutropenic (per protocol).

4. Treating cortisol excess (ketoconazole/metyrapone/osilodrostat) because very high cortisol suppresses immunity; controlling it lowers infection risk.

5. Nutrition + exercise + sleep (non-drug, but the most reliable “immunity support”).

6. Clinical trials of modern immunotherapy or cell therapies (when available) at expert centers.

I’m intentionally not fabricating “stem cell drugs” here—because none are proven for ACC at this time. PubMed

---

Surgeries

1. Open adrenalectomy with en bloc resection (gold-standard for localized ACC): the surgeon removes the adrenal tumor in one piece, often with surrounding fat and sometimes part of nearby organs if invaded; open approach is preferred to avoid tumor rupture. Why: best chance for cure when completely removed. The LancetPubMed

2. Regional lymphadenectomy: removal of nearby lymph nodes. Why: staging accuracy and may lower local recurrence risk. PubMed

3. IVC thrombectomy/resection (when tumor extends into veins): specialized vascular procedure. Why: restores blood flow and enables full tumor clearance. PubMed

4. Metastasectomy (lung/liver/bone lesions) in selected cases: removal of limited metastases. Why: may prolong survival and symptom control when feasible. PubMed

5. Cytoreductive (debulking) surgery for severe hormone excess when full removal isn’t possible. Why: reduces hormone output and improves quality of life alongside medical therapy. PubMed

---

Preventions

There’s no guaranteed way to prevent ACC. These steps reduce general cancer risks and improve early detection in higher-risk people:

1. Genetic counseling/testing if you or family have Li-Fraumeni, Lynch, or similar syndromes.

2. Regular surveillance for people with known high-risk genes (per specialist protocol).

3. Avoid tobacco; limit alcohol.

4. Healthy weight, active lifestyle.

5. Manage blood pressure, glucose, and cholesterol.

6. Limit unnecessary radiation exposure.

7. Know “red flag” hormone symptoms and seek assessment early.

8. Treat long-term steroid use carefully (medical supervision; tapering plans).

9. Balanced diet rich in whole foods (heart-healthy patterns).

10. Care at experienced centers if an adrenal mass is found, to avoid tumor rupture and delays. PubMed

---

When to see doctors

• Immediately/ER: severe weakness, vomiting, low blood pressure, confusion, high fever, or collapse—these can be signs of adrenal crisis, infection during chemo, blood clot, or electrolyte crisis. Carry your steroid emergency card if on replacement. Endocrine Society

• Urgently (days): rapidly rising blood pressure or blood sugar, worsening swelling/shortness of breath, painful leg swelling, or new neurological symptoms.

• Promptly (1–2 weeks): new Cushing-like changes, unexplained weight gain/loss, new menstrual/sexual changes, persistent abdominal/back pain, or a newly found adrenal mass.

---

What to eat and what to avoid

1. Protein at each meal (eggs, yogurt, fish, tofu, legumes) to maintain muscle during stress/therapy.

2. Colorful vegetables and fruits for fiber and micronutrients; wash well if neutropenic.

3. Whole-grain carbs for steady energy; spread intake if on steroids to limit glucose spikes.

4. Healthy fats (olive oil, nuts, seeds, fish).

5. Hydration (especially on mitotane or chemo); follow sodium guidance individualized to your hormone status.

6. If aldosterone excess or on fludrocortisone: your team will tailor potassium/sodium; don’t change drastically without advice.

7. Limit highly processed, very salty foods if blood pressure is high.

8. Limit sugary drinks/sweets if cortisol excess or on steroids.

9. Avoid alcohol around chemo and if liver tests are abnormal.

10. Discuss raw/undercooked foods with your team if neutropenic; food-safety matters during treatment.

---

FAQs

1. Is ACC curable? Yes—some patients are cured by complete surgery, especially in early stages. Advanced disease is harder but can be controlled with combined therapies. PubMed

2. Why is mitotane special? It targets adrenal cortical cells and is the only ACC-specific approved drug; blood levels are monitored closely. Endokrinologie

3. Do I always need chemo? Not always. After complete surgery, some patients receive adjuvant mitotane; chemotherapy is common for advanced or high-risk disease. Plans are individualized. PubMed

4. What is EDP-M? Etoposide, doxorubicin, cisplatin plus mitotane; it’s a standard first-line regimen for advanced ACC. PubMed

5. Can immunotherapy help? Sometimes, especially in specific tumor profiles (e.g., MSI-high). It’s not a guaranteed fix and is usually considered after standard options or in trials. PubMed

6. What if my tumor makes too much cortisol? Doctors rapidly lower cortisol with blockers (ketoconazole, metyrapone, osilodrostat) or receptor blocker (mifepristone) while treating the cancer. PubMed

7. Will I need steroid pills? Many patients on mitotane or after adrenal surgery need hydrocortisone (and sometimes fludrocortisone) replacement to prevent adrenal crisis. Endocrine Society

8. Is laparoscopic surgery OK? For suspected ACC, open surgery by an expert is typically preferred to avoid tumor rupture; approach is decided by your surgical team. The Lancet

9. What is the ENSAT stage? It classifies ACC by size/spread (I–IV) and helps guide treatment and follow-up. PubMed

10. Will treatment affect fertility or sex hormones? Yes, especially with hormone-secreting tumors or certain medicines; discuss fertility preservation and contraception early—mitotane reduces the effect of oral contraceptives. Endokrinologie

11. How often are scans and blood tests? Follow-up schedules are set by stage and therapy—typically frequent in the first 2–3 years, then spaced out. PubMed

12. Are there foods that “shrink” ACC? No. Nutrition supports strength and healing but does not replace medical care.

13. Should I seek a specialist center? Yes—outcomes are better when managed by teams with ACC expertise. The Lancet

14. What is my prognosis? It varies by stage, surgical completeness, and tumor biology. Your team will explain your individual outlook. PubMed

15. Where can I read trustworthy guidance? ESMO–EURACAN guidelines and NCCN resources are reliable starting points (health-professional versions are more technical). PubMedNCCN+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 08, 2025.